ABSTRACT
BACKGROUND. Ischemic stroke, a major cause of death and disability, triggers immune suppression and inflammation, increasing the risk of infections, particularly early post-stroke. These infections worsen outcomes, prolong hospitalization, and lack reliable predictive protocols. Current management with broad-spectrum antibiotics is not proven effective and may disrupt microbiota balance. Neutrophil elastase (NE), vital for immune defense, can exacerbate inflammation and infection susceptibility. The main objective of this study is to explore the role of NE in the development of infections after ischemic stroke.
METHODS. This study enrolled 544 ischemic stroke patients to evaluate NE as a biomarker for post-stroke infections. Data regarding age, sex, cardiovascular risk factors, stroke etiology and severity were collected. Blood samples from eligible patients, meeting strict inclusion and exclusion criteria, were analyzed using ELISA and multiplex assays to measure NE, myeloperoxidase, and immune mediators.
RESULTS. This study analyzed post-stroke infections in ischemic stroke patients, with 27.57% developing infections, respiratory (48.9%) and urinary (24.8%), mostly within three days. Infected patients were older, more often women, and diabetic, with higher NIHSS scores and larger infarct volumes. Elevated NE levels, higher leukocyte counts, and reduced lymphocytes at admission correlated with infection. Logistic regression showed NE, NIHSS, and diabetes as independent predictors. A matched case-control analysis confirmed higher NE levels in infected cases. Cytokine analysis revealed distinct immune profiles, with NE and IL-6 linked to respiratory infections.
CONCLUSIONS. NE levels at admission may help identify stroke patients at high infection risk, guiding targeted treatment and supporting potential anti-NE therapies and prophylactic antibiotic strategies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study was not registered because it is not a clinical trial
Funding Statement
This work was supported by grants from Spanish Ministry of Science and Innovation (MCIN) PID2022-140616OB-I00 (Dr Moro), from Leducq Trans-Atlantic Network of Excellence on Circadian Effects in Stroke TNE-21CVD04 (Drs Moro and Lizasoain), from Instituto de Salud Carlos III (ISCIII) and co-financed by the European Development Regional Fund ?A Way to Achieve Europe? PI23/00635, RICORS-ICTUS (Redes de Investigacion Cooperativa Orientadas a Resultados en Salud) RD21/0006/0001 and Programa FORTALECE-Instituto imas12, FORT23/00023 (Dr Lizasoain). The authors and their institutions have not received any payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patients providing informed consent to participate in this study, which had been formally approved by the ethics committee of the 12 de Octubre Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data referred to in the manuscript are available upon request
Non-standard Abbreviations and Acronyms
- CVRF
- cardiovascular risk factors
- MCA
- Middle cerebral artery
- MLRA
- Multiple logistic regression analysis
- MPO
- myeloperoxidase
- mRS
- modified Rankin Scale
- NE
- neutrophil elastase
- NETs
- Neutrophil extracellular traps
- NIHSS
- National Institutes of Health Stroke Scale
